{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T09:32:30Z","timestamp":1793179950932,"version":"4.5.0"},"reference-count":65,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Clin Pharmacol"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>This study aimed to compare how Norwegian healthcare professionals (HCPs) and consumers reported the same adverse event (AE) following immunization with vaccines against COVID\u201019 during the COVID\u201019 pandemic. Specifically, we aimed to compare the extent to which HCPs and consumers reported information relevant for assessing the causal relationship between the AE and the suspected COVID\u201019 vaccine, with a particular focus on the type of unstructured information provided by each group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Verified duplicate pairs of AE reports following COVID\u201019 vaccination were extracted from the Norwegian Adverse Drug Reaction Registry. Free\u2010text case narratives were analysed using thematic analysis to categorize types of unstructured information. A scoring system quantified completeness of causality\u2010relevant information, with final scores categorized into levels of completeness. Time intervals from AE onset to reporting were also calculated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:label\/>\n                    <jats:p>\n                      Nineteen categories of unstructured information were identified. HCPs more often provided vaccine dose details, clinical observations, test results and causality reflections, while consumers more often described dietary supplements, life consequences and subjective AE explanations (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u2009.05). In 85% of 127 duplicate pairs, HCPs and consumers provided at least 50% complementary information in free\u2010text narratives. Both groups provided similar levels of causality\u2010relevant information (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u2009.774). HCPs reported earlier than consumers (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u2009.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>HCPs and consumers provided highly complementary unstructured information and comparable completeness for causality assessment. Collaboration between these groups should be encouraged, particularly in public health and clinical emergencies like epidemics and in situations of high uncertainty.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/bcp.70648","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T07:45:42Z","timestamp":1782719142000},"page":"3559-3575","source":"Crossref","is-referenced-by-count":0,"title":["Do consumers and healthcare professionals report the same adverse event differently? A paired analysis of duplicate vaccine safety reports in Norway"],"prefix":"10.1002","volume":"92","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-8761-6623","authenticated-orcid":false,"given":"Tommy Emil","family":"Dzus","sequence":"first","affiliation":[{"name":"Faculty of Health Sciences, Institute for Natural Science and Health Oslo Metropolitan University  Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johaina","family":"Sarrage","sequence":"additional","affiliation":[{"name":"Faculty of Health Sciences, Institute for Natural Science and Health Oslo Metropolitan University  Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilde","family":"Samdal","sequence":"additional","affiliation":[{"name":"Norwegian Medical Product Agency  Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7056-8126","authenticated-orcid":false,"given":"Fran\u00e7ois","family":"Montastruc","sequence":"additional","affiliation":[{"name":"Department of Medical and Clinical Pharmacology, Centre of Pharmacovigilance and Pharmacoepidemiology, Faculty of Medicine Toulouse University Hospital (CHU)  Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5222-0238","authenticated-orcid":false,"given":"Elena","family":"Rocca","sequence":"additional","affiliation":[{"name":"Faculty of Health Sciences, Institute for Natural Science and Health Oslo Metropolitan University  Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,6,29]]},"reference":[{"key":"e_1_2_11_2_1","unstructured":"Helsedata Helsedata Norwegian Adverse Drug Reaction Registry 2025 retrieved January 13 2026 https:\/\/helsedata.no\/en\/forvaltere\/norwegian\u2010medical\u2010products\u2010agency\u2010noma\/norwegian\u2010adverse\u2010drug\u2010reaction\u2010registry\/"},{"key":"e_1_2_11_3_1","unstructured":"Statens legemiddelverk Bivirkningsrapport 2010 Statens legemiddelverk 2011 retrieved January 13 2026 https:\/\/www.dmp.no\/globalassets\/documents\/bivirkninger\u2010og\u2010sikkerhet\/rapporter\u2010og\u2010oversikter\/arsrapporter\/arsrapport\u2010bivirkninger\u20102010.pdf"},{"key":"e_1_2_11_4_1","unstructured":"European Medicines Agency ICH guideline E2B (R3) on electronic transmission of individual case safety reports (ICSRs)\u2014data elements and message specification\u2014implementation guide London: European Medicines Agency 2005updated August 27 2013 retrieved January 13 2026 https:\/\/www.ema.europa.eu\/en\/documents\/scientific\u2010guideline\/international\u2010conference\u2010harmonisation\u2010technical\u2010requirements\u2010registration\u2010pharmaceuticals\u2010human\u2010use\u2010guideline\u2010e2b\u2010r3\u2010electronic\u2010transmission\u2010individual\u2010case\u2010safety\u2010reports\u2010icsrs\u2010data\u2010elements_en.pdf"},{"key":"e_1_2_11_5_1","unstructured":"Lovdata Forskrift om system for rapportering av bivirkninger av legemidler (bivirkningsregisterforskriften)Oslo: Lovdata 2019 updated December 20 2023 retrieved January 13 2026 https:\/\/lovdata.no\/dokument\/SF\/forskrift\/2019-02-15-115"},{"key":"e_1_2_11_6_1","unstructured":"Helsenorge Report on adverse reactions to medicines and vaccines Oslo2020 retrieved January 13 2026 https:\/\/tjenester.helsenorge.no\/skjemautfyller\/SLV-PasRapp-2020?lang=en-GB"},{"key":"e_1_2_11_7_1","unstructured":"Statens legemiddelverk \u00c5rsrapport om bivirkninger 2022 Enhet for riktig legemiddelbruk Oslo: Statens legemiddelverk 2024 retrieved January 13 2026 https:\/\/view.publitas.com\/norwegian-medicines-agency-qqrogdeye7mm\/arsrapport-2022\/page\/6-7"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228\u2010022\u201003422\u2010y"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228\u2010025\u201003862\u20102"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4236"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264\u2010023\u201001355\u20108"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598\u2010025\u201007973\u20109"},{"key":"e_1_2_11_13_1","unstructured":"Direktoratet for Medisinske Produkter Meldte mistenkte bivirkninger av koronavaksiner\u2014Sluttrapport Oslo: Direktoratet for Medisinske Produkter 2025 updated March 18 2025 retrieved January 13 2026 https:\/\/www.dmp.no\/globalassets\/documents\/bivirkninger\u2010og\u2010sikkerhet\/rapporter\u2010og\u2010oversikter\/koronavaksiner\/rapport\u2010over\u2010meldte\u2010bivirkninger\u2010av\u2010koronavaksine\u2010\u2010\u2010oppsummeringsrapport.pdf"},{"key":"e_1_2_11_14_1","unstructured":"Statens legemiddelverk Meldte mistenkte bivirkninger av koronavaksiner pr. 21.09.2023 Oslo: Statens legemiddelverk 2023 updated September 25 2023 retrieved January 13 2026 https:\/\/www.dmp.no\/globalassets\/documents\/bivirkninger\u2010og\u2010sikkerhet\/rapporter\u2010og\u2010oversikter\/koronavaksiner\/20230925\u2010rapport\u2010over\u2010meldte\u2010bivirkninger\u2010av\u2010koronavaksine.pdf"},{"key":"e_1_2_11_15_1","unstructured":"Direktoratet for Medisinske Produkter The Norwegian Adverse Drug Reaction Registry Oslo: Direktoratet for Medisinske Produkter 2023 retrieved January 13 2026 https:\/\/www.dmp.no\/en\/adverse\u2010drug\u2010reactions\u2010and\u2010drug\u2010safety\/The\u2010Norwegian\u2010Adverse\u2010Drug\u2010Reaction\u2010Registry\u2010and\u2010reporting\u2010of\u2010adverse\u2010reactions\/ss"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365\u20102125.2006.02746.x"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264\u2010016\u20100441\u2010x"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13576"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.therap.2019.01.008"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264\u2010017\u20100530\u20105"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264\u2010016\u20100463\u20104"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264\u2010025\u201001573\u20102"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1080\/09581596.2024.2446763"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines13050481"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264\u2010024\u201001505\u20106"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264\u2010017\u20100548\u20108"},{"key":"e_1_2_11_27_1","unstructured":"Skatteetaten National identity numbers Oslo: Skatteetaten 2023 updated June 21 2023 retrieved January 13 2026 https:\/\/www.skatteetaten.no\/en\/person\/national\u2010registry\/identitetsnummer\u2010og\u2010elektronisk\u2010id\/fodselsnummer\/"},{"key":"e_1_2_11_28_1","unstructured":"National Institute of Public Health Norwegian Immunisation Registry SYSVAK Oslo: National Institute of Public Health 2021 [updated March 19 2025 retrieved January 13 2026 https:\/\/www.fhi.no\/en\/va\/norwegian-immunisation-registry-sysvak\/"},{"key":"e_1_2_11_29_1","unstructured":"European Medicines Agency Guideline on good pharmacovigilance practices (GVP) Module VI\u2014collection management and submission of reports of suspected adverse reactions to medicinal products (Rev 2) London: European Medicines Agency 2011 [updated July 28 2017 retrieved January 13 2026 https:\/\/www.ema.europa.eu\/en\/documents\/regulatory\u2010procedural\u2010guideline\/guideline\u2010good\u2010pharmacovigilance\u2010practices\u2010gvp\u2010module\u2010vi\u2010collection\u2010management\u2010and\u2010submission\u2010reports\u2010suspected\u2010adverse\u2010reactions\u2010medicinal\u2010products\u2010rev\u20102_en.pdf"},{"key":"e_1_2_11_30_1","unstructured":"European Medicines Agency Serious adverse reaction Amsterdam: European Medicines Agency 2024 retrieved January 13 2026 https:\/\/www.ema.europa.eu\/en\/glossary-terms\/serious-adverse-reaction"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264\u2010022\u201001258\u20100"},{"key":"e_1_2_11_32_1","unstructured":"World Health Organization The use of the WHO\u2010UMC system for standardised case causality assessment Geneva: World Health Organization 2013 retrieved January 13 2026 https:\/\/www.who.int\/docs\/default-source\/medicines\/pharmacovigilance\/whocausality-assessment.pdf"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17010014"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018\u2010200831010\u201000003"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1177\/003591576505800503"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018\u2010200225060\u201000012"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264\u2010017\u20100509\u20102"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.3389\/fdsfr.2023.1193413"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264\u2010026\u201001665\u20107"},{"key":"e_1_2_11_41_1","unstructured":"IBM Corp SPSS statistics 31 [Software] Chicago IL: IBM Corp;2025 retrieved January 13 2026 https:\/\/www.ibm.com\/products\/spss-statistics"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2009.252"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0028096"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/jep.12033"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2013.774371"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmedc.2009.01.004"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.1177\/009286158401800313"},{"issue":"2","key":"e_1_2_11_48_1","first-page":"265","article-title":"The causality assessment of adverse drug reactions using a Bayesian approach","volume":"3","author":"Lane D","year":"1987","journal-title":"Pharm Med"},{"key":"e_1_2_11_49_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552\u20104604.1994.tb03978.x"},{"key":"e_1_2_11_50_1","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000001836"},{"key":"e_1_2_11_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/0895\u20104356(93)90102\u20107"},{"key":"e_1_2_11_52_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3531"},{"key":"e_1_2_11_53_1","unstructured":"World Health Organization Causality assessment of an adverse event following immunization (AEFI) user manual for the revised WHO classification Geneva: World Health Organization;2019 updated 2019 retrieved December 05 2025 https:\/\/iris.who.int\/server\/api\/core\/bitstreams\/2a09fc09-127c-47e7-b289-e20523ded26b\/content"},{"key":"e_1_2_11_54_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2017.1383891"},{"key":"e_1_2_11_55_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3687"},{"key":"e_1_2_11_56_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13098"},{"key":"e_1_2_11_57_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264\u2010025\u201001560\u20107"},{"key":"e_1_2_11_58_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2019.1559812"},{"key":"e_1_2_11_59_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n1114"},{"key":"e_1_2_11_60_1","unstructured":"Norwegian Institute of Public Health Norwegian\u2010Danish study of rare side effects in connection with AstraZeneca vaccination published Oslo: Norwegian Institute of Public Health 2021 retrieved January 13 2026 https:\/\/www.fhi.no\/en\/news\/2021\/norwegian-danish-study-of-rare-side-effects-in-connection-with-astrazeneca\u2212\/."},{"key":"e_1_2_11_61_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228\u2010010\u20100865\u20107"},{"key":"e_1_2_11_62_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.5162"},{"key":"e_1_2_11_63_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228\u2010015\u20101867\u20102"},{"key":"e_1_2_11_64_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph18041507"},{"key":"e_1_2_11_65_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264\u2010019\u201000826\u20101"},{"key":"e_1_2_11_66_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264\u2010022\u201001222\u2010y"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bcp.70648","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/bcp.70648","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bcp.70648","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T08:36:27Z","timestamp":1793176587000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1002\/bcp.70648"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,29]]},"references-count":65,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1002\/bcp.70648"],"URL":"https:\/\/doi.org\/10.1002\/bcp.70648","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,29]]}}}